Cancers & treatments·Regimen libraryCurative

BV-AVD

Checked 2026-09-09

Stage III-IV classical Hodgkin lymphoma

One cycle

every 28 days × 6 · about 24 weeks in total

28-day cycle × 6 (about 24 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Brentuximab vedotin ADC	1.2 mg/kg	IV	D1, 15
Doxorubicin Cytotoxic chemotherapy (anthracycline)	25 mg/m²	IV	D1, 15
Vinblastine Vinca alkaloid (microtubule inhibitor)	6 mg/m²	IV	D1, 15
Dacarbazine	375 mg/m²	IV	D1, 15

Cycles

6

28-day cycle

Emetogenicity

High (>90%)

G-CSF

Recommended

Notes

Primary G-CSF prophylaxis after excess febrile neutropenia in the trial; peripheral neuropathy in two-thirds.

Used in

Hodgkin lymphoma

Trials

Products

Brentuximab vedotinDoxorubicinVinblastine

Source

ECHELON-1, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage

every 28 days × 2-6

N-AVD (nivolumab + AVD)

Stage III-IV classical Hodgkin lymphoma, age 12 and above

every 28 days × 6

Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)

every 14 days × 2-3

Escalated BEACOPP

Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles

every 21 days × 4-6

Historical: the first curative combination chemotherapy for advanced Hodgkin lymphoma (1960s to 1980s), replaced by ABVD

every 28 days × 6

Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial

every 28 days × 3

Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy

every 21 days × 4-5

OEPA (vincristine, etoposide, prednisone, doxorubicin)

Induction for children and adolescents with Hodgkin lymphoma in the European EuroNet-PHL protocols; OPPA (procarbazine instead of etoposide) was the earlier version used in girls

every 28 days × 2

All regimens N-AVD (nivolumab + AVD) →